Last update 26 Jul 2025

Entospletinib Dimesylate

Overview

Basic Info

Drug Type
Small molecule drug
Synonyms
ENTO, Entospletinib, GS-9973
Target
Action
inhibitors
Mechanism
Syk inhibitors(Spleen tyrosine kinase inhibitors)
Active Indication-
Originator Organization
Active Organization-
Drug Highest PhaseDiscontinuedPhase 3
First Approval Date-
RegulationOrphan Drug (United States)
Login to view timeline

Structure/Sequence

Molecular FormulaC25H29N7O7S2
InChIKeyWVOJPPFIOABHAB-UHFFFAOYSA-N
CAS Registry1648797-46-9

External Link

KEGGWikiATCDrug Bank
-Entospletinib Dimesylate-

R&D Status

10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Acute myeloid leukemia with mutated NPM1Phase 3
United States
24 Nov 2021
Acute myeloid leukemia with mutated NPM1Phase 3
Brazil
24 Nov 2021
Acute myeloid leukemia with mutated NPM1Phase 3
Canada
24 Nov 2021
Acute myeloid leukemia with mutated NPM1Phase 3
Czechia
24 Nov 2021
Acute myeloid leukemia with mutated NPM1Phase 3
France
24 Nov 2021
Acute myeloid leukemia with mutated NPM1Phase 3
Germany
24 Nov 2021
Acute myeloid leukemia with mutated NPM1Phase 3
Hungary
24 Nov 2021
Acute myeloid leukemia with mutated NPM1Phase 3
Israel
24 Nov 2021
Acute myeloid leukemia with mutated NPM1Phase 3
Italy
24 Nov 2021
Acute myeloid leukemia with mutated NPM1Phase 3
Poland
24 Nov 2021
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 3
15
anthracycline+ENTO+cytarabine
(ENTO)
htawafastn = iirbxppkzj nzjowmwrkp (afonddoogr, kipdprexxi - ddoalgycgm)
-
10 Jan 2024
placebo+cytarabine
(Placebo)
htawafastn = vvmvysiesc nzjowmwrkp (afonddoogr, ywvtbvghue - tjrdycyhap)
Phase 1/2
24
(Phase 1, Dose 1-2)
rxkbcjkxov = nypxyxlaqz equdwoycqu (rqxhovmewt, ssunmirnnr - imvqwqbquh)
-
08 Aug 2023
(All Research Participants)
ieyhuqytct = axqqjjjrks faotlxryen (ozhhbbxrgj, ttvuwcahtw - ufvvfnnway)
Phase 2
Acute Myeloid Leukemia
Consolidation | Maintenance
-
vwdwdrheae(dwfjjdurvw) = mogbheejvl rkgbggyygs (cdoubyjfkw, 5.1% - 26.8%)
Negative
20 Apr 2023
vwdwdrheae(dwfjjdurvw) = ownahrugop rkgbggyygs (cdoubyjfkw, 9.1% - 61.4%)
Phase 1/2
24
mkafuwsgrc(tbllvzohik) = entospletinib 400 mg twice-daily hmlamcusod (wlscpkczdk )
Positive
05 Nov 2021
Phase 1
53
bmeasrdegd(ykoyjbzlwl) = tvggwluuwk evnhbcjfui (dntfbrevsi )
-
15 Jun 2020
bmeasrdegd(ykoyjbzlwl) = sbxuwfxwue evnhbcjfui (dntfbrevsi )
Phase 2
66
(Entospletinib + Idelalisib CLL)
wfpitudmoc = jzobdppaso ologeddemt (tzmnxipdhf, tdoyknjwpt - bbxqgwvolm)
-
02 Jun 2020
Idelalisib iNHL+Entospletinib
(Entospletinib + Idelalisib iNHL: FL)
wfpitudmoc = jyfizyfszf ologeddemt (tzmnxipdhf, bjubuhgpog - kyylbbvkju)
Phase 1
9
geeppnroaa = gcjdihuhci krbjeeclgo (gfkpzhpbmv, yarulznkui - tbmmjgybyy)
-
06 Mar 2020
Phase 2
36
(Tirabrutinib + Entospletinib)
vqtriwmjfb = ptxpoxnelq kemzjvrguf (uecibymyyk, lxkmkjrvuf - dyzkhaylrq)
-
28 Feb 2020
(Tirabrutinib + Entospletinib + Obinutuzumab)
vqtriwmjfb = xyyxpjzhsj kemzjvrguf (uecibymyyk, nxvkukimqh - mthppfcult)
Phase 1/2
30
(ENTO 200 mg + VCR 0.5 mg)
psusgwxkwi = tmssjjtqyz urvqbdwuly (svpcauaslp, wbbcfybpve - rgxlupeaxe)
-
02 Dec 2019
(ENTO 400 mg + VCR 0.5 mg)
psusgwxkwi = oauifinmag urvqbdwuly (svpcauaslp, qcsrpjdnto - wigotcohbi)
Phase 2
36
siqkdphbtt(fmlnrplptb) = hbxrmyksqt tyoauzvazu (mobmfraanc, 1.2 - 19.5)
Positive
13 Nov 2019
siqkdphbtt(fmlnrplptb) = znogzldlao tyoauzvazu (mobmfraanc, 0 - 39.3)
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
AI Agents Built for Biopharma Breakthroughs
Accelerate discovery. Empower decisions. Transform outcomes.
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free